Optum: More Naloxone Options Coming to Market

A high-dose opioid antagonist and generic versions of a nasal spray commonly used to reverse overdoses are both hitting the market, according to an update from Optum Workers’ Comp and Auto No-Fault. In October 2021, the U.S. Food and Drug Administrative approved a higher-dosage naloxone injection — ZIMHI — to treat overdoses. The approval followed the FDA green-lighting Kloxxado, a high-dose naloxone nasal spray. “Like Kloxxado, ZIMHI is another tool to help combat the surge in overdose deaths due to opioid analgesics, particularly since stronger opioid analgesics or ...